Welcome to our dedicated page for Eagle Pharmaceut news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceut stock.
Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) generates a steady flow of corporate, product and governance updates that are relevant to investors following EGRX news. As a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, Eagle regularly issues press releases about its commercial portfolio, pipeline programs and capital structure decisions.
Company announcements describe a portfolio that includes PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO, as well as BYFAVO and BARHEMSYS historically commercialized through its wholly owned subsidiary Acacia Pharma Inc. News items have covered transactions such as a royalty purchase agreement to monetize BENDEKA royalties and the divestiture of the U.S. marketing authorization for Barhemsys (amisulpride) to LXO Group, with Eagle noting that proceeds would support ongoing operations and debt repayment.
Governance and capital markets developments are also a recurring theme in Eagle’s news flow. The company has reported on the adoption and amendment of a limited duration stockholder rights plan, changes to the plan’s purchase price and duration, and cooperation agreements with significant stockholders involving board appointments. In addition, Eagle issues updates on its annual meeting of stockholders, proxy material availability, and the release of audited and unaudited financial statements.
Investors monitoring EGRX news can use this page to follow Eagle’s disclosures on its oncology and critical care products, CNS/metabolic critical care pipeline, financing transactions, and corporate governance actions. Regularly reviewing these updates can help readers understand how Eagle describes the evolution of its product portfolio, pipeline priorities and capital structure over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.